Eli Lilly submits tirzepatide for approval in US and EU

Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide, the US-based pharmaceutical firm announces, also reporting that applications for seven additional markets have been submitted.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Eli Lilly's tirzepatide, presumably the biggest contender for Novo Nordisk's newest generation of diabetes drugs, has taken a pivotal step on the pathway toward future market launches.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading